Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia.

Trial Profile

Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2011

At a glance

  • Drugs Emtricitabine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms TEmAA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2009 Additional trial acronym TEmAA identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top